S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
ASX:BD1

BARD1 Life Sciences (BD1) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free BD1 Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
801,545 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BD1 stock logo

About BARD1 Life Sciences Stock (ASX:BD1)

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

BD1 Stock News Headlines

March 14, 2023 | npr.org
Life Kit
February 12, 2023 | theguardian.com
Take AstraZeneca’s warning seriously. The UK is missing out in life sciences
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
February 5, 2023 | cnet.com
See a Real-Life 'Terminator' Robot Turn Into Liquid to Bust Out of a Cage
January 14, 2023 | bizjournals.com
Bay Area's biggest life science stock winners and losers in 2022
January 13, 2023 | finance.yahoo.com
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
November 17, 2022 | marketwatch.com
SELLAS Life Sciences Group Shares Drop 40% on Clinical Trial Update
October 13, 2022 | techcrunch.com
Quantori is building an app development platform focused on life sciences
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
August 25, 2022 | finance.yahoo.com
BD Promotes Two Senior Executives to Segment Leadership Roles
December 9, 2021 | msn.com
Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?
November 12, 2021 | fool.com.au
BARD1 (ASX:BD1) share price ends stellar day up 41%
November 11, 2021 | msn.com
BARD1 Life Sciences (ASX:BD1) share price leaps 15% on US patent news
August 17, 2021 | msn.com
BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update
July 30, 2021 | msn.com
Here’s why the BARD1 (ASX:BD1) share price is falling 7% today
July 26, 2021 | proactiveinvestors.com.hk
BARD1 Life Sciences raises $15 million to accelerate cancer diagnostic test development
July 23, 2021 | msn.com
BARD1 (ASX:BD1) share price falls 6% on placement update
See More Headlines
Receive BD1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:BD1
CUSIP
N/A
CIK
N/A
Web
www.bard1.com
Phone
61 8 9381 9550
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
4.35
Current Ratio
3.87
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$1.27 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
4.33
Book Value
A$0.36 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
92,018,704
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Leearne Maree Hinch BSc.
    B.V.M.S., M.R.C.V.S., M.B.A., Chief Exec. Officer
  • Mr. Peter Lynton Gunzburg B Comm (Age 69)
    ASIA, Managing Director
    Comp: $82.12k
  • Mr. Tony Di Pietro AGIA
    C.A., M.A.I.C.D., B.Com, CPA, CFO & Joint Company Sec.
  • Mr. Carl S. Stubbings
    Chief Operating Officer
  • Dr. Peter William French M.B.A.
    B.Sc., M.Sc., Ph.D., MBA, FRSM, Chief Scientific Officer
  • Ms. Pauline Anne Collinson (Age 65)
    Joint Company Sec.

Key Competitors

View All Competitors

This page (ASX:BD1) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
How Biden has already won 2024
Porter & Company